High grade B-cell lymphoma Burkitt-like lymphoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:29:30 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png High grade B-cell lymphoma Burkitt-like lymphoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma https://clinicaltrials.eu/trial/study-on-acalabrutinib-with-rituximab-and-drug-combination-for-older-adults-with-untreated-diffuse-large-b-cell-lymphoma/ Wed, 29 Apr 2026 14:24:39 +0000 https://clinicaltrials.eu/trial/study-on-acalabrutinib-with-rituximab-and-drug-combination-for-older-adults-with-untreated-diffuse-large-b-cell-lymphoma/ This clinical trial is focused on studying the effectiveness of a treatment for , a type of cancer that affects the white blood cells. The study involves a combination of medications, including , , and a reduced dose of a chemotherapy regimen known as R-miniCHOP. R-miniCHOP includes several drugs: , , , , and . The purpose of the study is to determine if adding acalabrutinib to the R-miniCHOP treatment can help patients live longer without the disease getting worse, compared to using R-miniCHOP alone.

Participants in the study will receive either the combination of acalabrutinib with R-miniCHOP or R-miniCHOP alone. The study is designed for older adults who have not been treated for DLBCL before. The treatment will be administered over a period of time, with regular check-ups to monitor the patient’s health and the progression of the disease. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

The study aims to provide valuable information on whether the addition of acalabrutinib can improve outcomes for patients with DLBCL. The results will help doctors understand if this combination of treatments is more effective than the standard R-miniCHOP therapy. This research is important for developing better treatment options for patients with this type of lymphoma.

]]>